FDA Stalling On Impulsivity Warnings For Drugs: Nonprofit
A Washington, D.C.-based consumer advocacy group asked a federal court on Monday to force the U.S. Food and Drug Administration to act on its 2016 petition saying dopamine agonist drugs should...To view the full article, register now.
Already a subscriber? Click here to view full article